Yang RH, Xu Q, Qiao YY, Jia HZ, Shi XL. Experimental study of herbal-based medicine Hong Tian Gan Kang on the intervention and therapy for hepatic cirrhosis.
Shijie Huaren Xiaohua Zazhi 2008;
16:582-589. [DOI:
10.11569/wcjd.v16.i6.582]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To investigate the prevention and treatment of Hong Tian Gan Kang (HTGK) on experimental hepatic cirrhosis.
METHODS: The female ICR mice were allocated into traditional Chinese medicine (HTGK) prevention group, treatment group, animal model group, and control group. During the process of inducing hepatocirrhosis by CCl4 celiac injection in ICR mice, the HTGK group received HTGK per day, while the model group was created into the animal model by the above means without treatment. The mice of control group were normally raised without being created into models. The control group, animal model group and (HTGK) prevention group were sacrificed randomly at the end of the 60 d, 90 d and 180 d; while treatment group was sacrificed randomly at the end of the 30 d, 60 d and 90 d. Tissue specimens were taken. Animals received liver histopathology and ultrastructure test.
RESULTS: Up to day 180, marked hepatic fatty changes, inflammation, necrosis and fibrosis were observed in mice of model group. In contrast, these alternations were attenuated by HTGK administration although mild fatty changes remained. Compared with the CCl4-induced cirrhotic mice, histological changes of fibrosis were improved significantly in the mice treated with HTGK. Liver histopathology showed that the contents of transforming growth factor-β1 (TGF-β1) and alpha-smooth muscle actin (α-SMA) in the animal model group were significantly higher than those in the control group (TGF-β1, 60 d: 0.269 vs 0.155; 90 d: 0.306 vs 0.155; 180 d: 0.336 vs 0.160; α-SMA, 60 d: 0.269 vs 0.160; 90 d: 0.299 vs 0.150; 180 d: 0.322 vs 0.155, P < 0.01). However, the contents of TGF-β1 and α-SMA in the therapy group were significantly lower than those in the model group (0.220, 0.203, 0.185 vs 0.336, P < 0.01; 0.2451, 0.2113, 0.185 vs 0.3217, P < 0.01).
CONCLUSION: HTGK has suppressive, preventive and curative effect on hepatic fibrosis and hepatocirrhosis.
Collapse